Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Important Safety Information | Patient Site
Prescribing Information
Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, 300 mg pens logo

Alhemo® is a tissue factor pathway inhibitor (TFPI)-antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors.

Prescribing Information
Important Safety Information | Patient Site

Helpful patient support tools for health care professionals

NovoCare® offers resources to help you support your patients throughout their treatment. Check their insurance, understand what the insurer requires, and see savings offers and product assistance programs.

Daughter hugging her mother

NovoCare® is designed for your patients

Start with the Patient Enrollment Form to enroll your patients in any NovoCare® support programs.

You can visit NovoCare.com to download a PEF or call NovoCare® at
1-844-668-6732.

NovoCare® is available to help with:

Case manager access support

Case manager access support icon

Insurance navigation support including benefit investigations, prior authorizations and appeals, and LMN templates

Interim program
 

Interim program icon

For eligible patients on therapy who experience a gap in their commercial insurance coveragea

Savings offer
 

Saving money icon

Eligible, commercially insured patients may pay as little as $0 per fill, for a maximum benefit of $15,000 annuallya

Patient Assistance Program (PAP)

Patient assistance icon

NovoCare® can help patients with financial barriers to treatment.a

onboarding support icon

Patient liaison onboarding support

NovoCare team works with patients as they onboard their new medication and can provide device training

Patient liaison
onboarding support

Patient assistance icon

NovoCare team works with patients as they onboard their new medication and can provide device training

aEligibility and restrictions apply. See Terms & Conditions at NovoCare.com
1+ 844-668-6732 from 8:00 AM to 8:00 PM, Monday through Friday EST

LMN=Letter of Medical Necessity.

Additional resources for patients

Co-pay Assistance Program
website

Interim Product Program

Hands and plus sign icon

This limited program provides hemophilia therapy to qualifying patients during a coverage gap. Contact a NovoCare® Specialist by calling 1-844-668-6732.

Important Safety Information for Alhemo®

Contraindications

  • Alhemo® is contraindicated in patients with a history of known serious hypersensitivity to Alhemo® or its ingredients

Warnings and Precautions

  • Thromboembolic Events (TEs): Venous and arterial TEs were reported in 1.3% of patients (4/320) who also had multiple risk factors, including the use of high doses or prolonged treatment with factor products or bypassing agents (2 of 4 events). Risk factors for TEs may also include conditions in which tissue factor is overexpressed (eg, atherosclerotic disease, crush injury, cancer, disseminated intravascular coagulation, thrombotic microangiopathy, or septicemia).
    Inform patients about and monitor them for signs and symptoms of TEs. In case of suspicion of TEs, discontinue Alhemo® and initiate further investigations and management strategies

Indications and Usage

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A with FVIII inhibitors and hemophilia B with FIX inhibitors.

Important Safety Information cont'd

Warnings and Precautions cont'd

  • Hypersensitivity Reactions: Alhemo® is contraindicated in patients with a history of known serious hypersensitivity to Alhemo® or its ingredients. Hypersensitivity reactions, including erythema, rash, pruritus, and abdominal pain, have occurred in patients treated with Alhemo®. One patient (<1%) experienced anaphylaxis, which resolved after treatment with antihistamines and corticosteroids. Instruct patients of the signs of acute hypersensitivity reactions and to contact their healthcare provider for mild reactions and to seek urgent medical attention for moderate to severe reactions. Discontinue Alhemo® if severe hypersensitivity symptoms occur, and initiate medical management
  • Increased Laboratory Values of Fibrin D-dimer and Prothrombin Fragment 1.2: Increased levels of fibrin D-dimer and prothrombin fragment 1.2 were seen in 29 (9.1%) and 18 (5.6%) patients, respectively, which is positively correlated with the plasma concentration of concizumab-mtci, indicating a hemostatic effect. For patients taking Alhemo®, these coagulation biomarkers may not be reliable predictive markers for clinical decision-making with suspicion of thrombosis, such as deep vein thrombosis and pulmonary embolism

Adverse Reactions

  • The most frequently reported adverse reactions (≥5%) were injection site reactions and urticaria
  • Serious adverse reactions were reported in 6.1% of patients who received Alhemo®. Permanent discontinuation of Alhemo® occurred in 1 patient due to a renal infarct and dosage interruptions of Alhemo® occurred in 1 patient (3%) and was a hypersensitivity reaction

Drug Interactions

  • Bypassing Agents (BPAs): Take appropriate precautions when treating breakthrough bleeding events in hemophilia patients receiving Alhemo® prophylaxis and a BPA (eg, rFVIIa or aPCC). For mild and moderate bleeds, the lowest approved dose in the approved BPA product labeling is recommended. For aPCC, a maximum dose of 100 units/kg within 24 hours is recommended. For severe bleeds, follow the dosing instructions in the approved labeling based on clinical judgment

Please click here for Alhemo® Prescribing Information.